Home › Metastatic Cancer › NCT04842266
IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pelvis Fractures
A Prospective Study of the IlluminOss Photodynamic Bone Stabilization System for the Treatment of Impending and Actual Pathological Fractures in the Pelvis From Metastatic Bone Disease or Geriatric Pelvic Fractures
Who can join
Ages 21 and older · All sexes
Full eligibility criteria
Inclusion criteria: Patients are being targeted because they have already agreed to the undergo the IlluminOss Pelvic Implant for standard clinical care. It is a decision made by the treating surgeon separately from research and prior to mention of the study. 1. Patient is a skeletally mature patient 21 years of age or older (closed epiphyseal plates) who receiving the FDA-approved IlluminOss Pelvic Implant 2. IlluminOss Pelvic Implant is intended to treat pain due to impending or actual non-displaced or minimally displaced pathologic fractures of the pelvis secondary to metastatic malignancy, multiple myeloma, lymphoma, or radiation osteitis or a pelvic fragility fracture in a geriatric patients (age 65 or older) 3. VAS Pain Score ≥ 30 on 0 to 100 scale Exclusion criteria: 1. Patient is uncooperative, or patient incapable of following directions (for example, as a consequence of a neurological or psychiatric disorder) 2. Patient is a prisoner 3. Patient is deemed surgically unfit by the medical oncology service
About the study
The aim of this project is to assess the effectiveness of the IlluminOss pelvic implants in patients with pelvic metastatic disease presenting with pain, risk of pathologic fracture, non-displaced or minimally displaced pathologic fracture of the pelvis, and geriatric patients with pelvic fragility fractures. Results from this study will be used to confirm preliminary clinically and possibly statistically significant reductions in pain and improvements in function among these patients.
What is being tested
- IlluminOss pelvic implant for oncologic indication (device)
- IlluminOss pelvic implant for geriatric trauma indication (device)
Sponsor: Massachusetts General Hospital · Participants: 100 · Started: Nov 18, 2021
Contact the study team
- Kevin Raskin, MD · Phone: 617-724-3700
- Shreya Halur, BS · Phone: 617-726-4932
Official record on ClinicalTrials.gov — NCT04842266
Locations in the U.S.
| Massachusetts | Massachusetts General Hospital, Boston |
Conditions
From ClinicalTrials.gov, data retrieved Sep 30, 2026. Each study sets its own eligibility; the study team decides who can join.